Back to results
US 9,364,504 B2Granted
Compostition and therapeutic anti-tumour vaccine
AssigneeErytech Pharma
InventorsYann Godfrin, Alice Banz
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeErytech Pharma
InventorsYann Godfrin, Alice Banz
Estimating the term…
The invention relates to a composition which induces, in a host, a cytotoxic cell response directed against cells expressing an antigen, in particular tumor cells, and which comprises red blood cells containing said antigen. These red blood cells may be in the form of an immune complex with an immunoglobulin, in particular IgG, which recognizes an epitope at the surface of the red blood cells, and/or be heat-treated or chemically treated so as to promote phagocytosis of said red blood cells by dendritic cells. As a variant, the red blood cells may be xenogenic red blood cells. The invention also relates to a therapeutic especially anti-tumor vaccine containing such a composition.
A pharmaceutically acceptable injectable or infusible pharmaceutical comprising a non-naturally-occurring suspension of red blood cells containing a tumor antigen inside of said red blood cells, wherein the suspension comprises the red blood cells at a haematocrit level of between 40 and 70%, a pharmaceutically acceptable injectable or infusible saline buffer comprising NaCl and an ingredient selected from the group consisting of adenine, glucose and mannitol, and a pharmaceutically acceptable adjuvant for activating dendritic cell maturation, wherein said composition is capable of inducing a cytotoxic cellular response against tumor cells in a host.
A pharmaceutically acceptable injectable or infusible composition comprising a non-naturally-occurring suspension of red blood cells containing a tumor antigen inside of said red blood cells, a pharmaceutically acceptable injectable or infusible saline buffer comprising NaCl and an ingredient selected from the group consisting of adenine glucose and mannitol, and a pharmaceutically acceptable adjuvant for activating dendritic cell maturation, and a injectable buffer, wherein said composition is capable of inducing a cytotoxic cellular response against tumor cells in a host.
A pharmaceutically acceptable injectable or infusible composition comprising a non-naturally-occurring suspension of red blood cells containing a tumor antigen inside of said red blood cells, and a pharmaceutically acceptable injectable or infusible saline buffer comprising NaCl and an ingredient selected from the group consisting of adenine, glucose and mannitol.
Dependencies are inferred from the claim text.